SkinMedica, Inc. announced a collaboration with Massachusetts General Hospital (MGH) for the research and development of pigmentation products. The skin care brand and hospital have entered into an exclusive agreement to screen and evaluate a library of roughly 40,000 natural extracts made available by the National Cancer Institute for potential applications in skin pigmentation.
The principal investigator for this collaborative effort is David Fisher, MD, PhD, chief of the Massachusetts General Hospital department of dermatology, director of the MGH Cutaneous Biology Research Center and director of the Melanoma Center at MGH.
"We are delighted to have the opportunity to collaborate with Dr. Fisher, a world leader in dermatology research," said Mary Fisher, CEO of SkinMedica. "His expertise in pigment and the skin's environmental responses will be invaluable as we together pursue novel approaches for patients with a variety of pigment related concerns."
"With this collaboration, we can progress our screening work toward understanding the role of natural products in supporting or inhibiting the processes that generate pigment, and to identifying practical solutions for these patients," said Dr. Fisher. "Hyperpigmentation is one of the most frequently cited concerns resulting in patient visits to a dermatologist, with the most common forms being melasma, solar lentigines and post-inflammatory hyperpigmentation."
